Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Gains from Investment Securities (2020 - 2025)

Greenwich LifeSciences filings provide 6 years of Gains from Investment Securities readings, the most recent being $893181.0 for Q3 2025.

  • Quarterly Gains from Investment Securities fell 40.38% to $893181.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $893181.0 through Sep 2025, down 40.38% year-over-year, with the annual reading at $893181.0 for FY2024, 0.0% changed from the prior year.
  • Gains from Investment Securities hit $893181.0 in Q3 2025 for Greenwich LifeSciences, roughly flat from $893181.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.5 million in Q1 2023 and bottomed at $594522.0 in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $1.1 million, with a median of $908242.0 recorded in 2021.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 297.48% in 2021 before it crashed 40.38% in 2025.
  • Greenwich LifeSciences' Gains from Investment Securities stood at $908242.0 in 2021, then plummeted by 34.54% to $594522.0 in 2022, then skyrocketed by 50.24% to $893181.0 in 2023, then changed by 0.0% to $893181.0 in 2024, then changed by 0.0% to $893181.0 in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Gains from Investment Securities are $893181.0 (Q3 2025), $893181.0 (Q2 2025), and $893181.0 (Q1 2025).